Kidney Disease Clinical Trials

Showing 421-440 of 3,346 trials

Stereotactic Magnetic Resonance Guided Radiation Therapy

NCT04115254

This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer. * The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer. * Phase 2 will evaluate efficacy of SMART with specific reference to tumor control and improvement in patient reported outcome measures

Pancreas CancerLung CancerRenal Cancer+10 more

Dana-Farber Cancer Institute397 participantsStarted Oct 2019

Boston, Massachusetts, United States • Boston, Massachusetts, United States

Active Not RecruitingNA

PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer

NCT02735252

This is a tissue and blood collection protocol requiring image-guided biopsies of metastatic prostate cancer and other genitourinary malignancies including renal cell carcinoma and urothelial carcinoma. Whenever possible, a new bone lesion or new/progressing soft tissue lesion will be chosen for biopsy as opposed to radiographically stable lesion. Patients will be enrolled in into one of several parallel cohorts based upon disease status or type and the planned systemic therapy following baseline tumor biopsy: (A) Androgen signaling inhibition, (B) Immunotherapy, (C) Radiotherapy, (D) Targeted Therapy/Investigational therapeutic, (E) DNA damage response pathway, (F) Aggressive variant disease, (G1) Castration-sensitive ADT naïve and ADT \< 3 months), or (G2) Castration-sensitive pre-treated with sub-optimal PSA nadir \>0.2 ng/ml, (R) metastatic renal cell carcinoma and metastatic and (U) urothelial carcinoma.

Prostate CancerAdvanced Renal Cell CarcinomaAdvanced Urothelial Carcinoma+1 more

University of California, San Francisco156 participantsStarted May 2016

San Francisco, California, United States

Stereotactic Magnetic Resonance Guided Radiation Therapy

PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer

Related Searches

Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble

Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer

Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Dissemination of the Donor Application: Utilizing Social Media to Identify Potential Live Organ Donors

Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

Prevention of Serious Adverse Events Following Angiography

Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1

Operator and Patient Acceptance of Radiofrequency Cautery of the Biopsy Track During Percutaneous Liver, Kidney or Spleen Biopsy Procedures.

Rutgers University Study of the Genetics of Kidney Disease

Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma

Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease

Comparing Surgical and Endovascular Arteriovenous Fistula Creation

Evaluation of the Safety and Tolerability of Gemini in Subjects With Stage 3-4 Chronic Kidney Disease.

Prospective Evaluation of Blunt Renal Injury in Children

Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function

Prospective Phenotyping of Autonomous Aldosterone Secretion

Mindfulness in Chronic Kidney Disease